<?xml version='1.0' encoding='utf-8'?>
<document id="20937004"><sentence text="In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies." /><sentence text="AZD2624 was pharmacologically characterized as a NK3 receptor antagonist intended for treatment of schizophrenia"><entity charOffset="0-7" id="DDI-PubMed.20937004.s2.e0" text="AZD2624" /></sentence><sentence text=" The metabolic drug-drug interaction potential of AZD2624 was evaluated in in vitro studies" /><sentence text=" CYP3A4 and CYP3A5 appeared to be the primary enzymes mediating the formation of pharmacologically active ketone metabolite (M1), whereas CYP3A4, CYP3A5, and CYP2C9 appeared to be the enzymes responsible for the formation of the hydroxylated metabolite (M2)"><entity charOffset="106-112" id="DDI-PubMed.20937004.s4.e0" text="ketone" /></sentence><sentence text=" The apparent K(m) values were 1" /><sentence text="5 and 6" /><sentence text="3 µM for the formation of M1 and M2 in human liver microsomes, respectively" /><sentence text=" AZD2624 exhibited an inhibitory effect on microsomal CYP3A4/5 activities with apparent IC(50) values of 7" /><sentence text="1 and 19" /><sentence text="8 µM for midazolam and testosterone assays, respectively"><entity charOffset="23-35" id="DDI-PubMed.20937004.s10.e0" text="testosterone" /></sentence><sentence text=" No time-dependent inactivation of CYP3A4/5 activity (midazolam 1'-hydroxylation) by AZD2624 was observed" /><sentence text=" AZD2624 demonstrated weak to no inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6" /><sentence text=" AZD2624 was not an inducer of CYP1A2 or CYP2B6" /><sentence text=" Although AZD2624-induced CYP3A4 activity in hepatocytes, the potential of AZD2624 to cause inductive drug interactions of this enzyme was low at relevant exposure concentration" /><sentence text=" Together with targeted low efficacious concentration, the results of this study demonstrated AZD2624 has a relatively low metabolic drug-drug interaction potential towards co-administered drugs"><entity charOffset="94-101" id="DDI-PubMed.20937004.s15.e0" text="AZD2624" /></sentence><sentence text=" However, metabolism of AZD2624 might be inhibited when co-administrated with potent CYP3A4/5 inhibitors" /><sentence text="" /></document>